Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Novocure und Roche kooperieren bei klinischen Studien, um Tumortherapiefelder als Teil einer neuartigen Kombination zur Erstbehandlung von metastasierendem Bauchspeicheldrüsenkrebs zu prüfen: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure und Roche kooperieren bei klinischen Studien, um Tumortherapiefelder als Teil einer neuartigen Kombination zur Erstbehandlung von metastasierendem Bauchspeicheldrüsenkrebs zu prüfen


Novocure (NASDAQ: NVCR) gab heute den Abschluss eines Vertrags zur Zusammenarbeit mit Roche (SIX: RO. ROG; OTCQX: RHHBY) im Rahmen klinischer Studien bekannt. Ziel ist die Entwicklung von

Agilent Announces Thought Leader Award to Bernhard Lendl at the TU Wien (Vienna): https://unsplash.com/photos/MJX7-BAdkt0
Agilent Announces Thought Leader Award to Bernhard Lendl at the TU Wien (Vienna)


Agilent Technologies Inc. (NYSE: A) today announced Professor Bernhard Lendl has been selected to receive a prestigious Agilent Thought Leader Award. Highly renowned in the field of vibrational

Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Agehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they have submitted data to the U.S. Food and Drug Administration (FDA) from the Phase 2/3 trial of their COVID-19 vaccine in

Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Programhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program


Pfizer Inc. (NYSE: PFE) announced today that the first participants have been dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of a single dose

Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults


Pfizer Inc. (NYSE: PFE) today announced the start of the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study to evaluate the investigational novel

Dr. Mikael Dolsten Named to Agilent Board of Directors:
Dr. Mikael Dolsten Named to Agilent Board of Directors


Agilent Technologies, Inc. (NYSE: A) today announced that Dr. Mikael Dolsten, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer Inc. has been elected to

Humana and Kelsey-Seybold Clinic Team up to Expand Access to Value-based Care, Broadening Humana’s Medicare Advantage Provider Network in the Greater Houston Area: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana and Kelsey-Seybold Clinic Team up to Expand Access to Value-based Care, Broadening Humana’s Medicare Advantage Provider Network in the Greater Houston Area


Humana, a leading health and well-being company, and Kelsey-Seybold Clinic have signed an in-network agreement, expanding access to care to include members of Humana Medicare Advantage HMO plans.

Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analystshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analysts


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 2, 2021. The

Simulations Plus Receives New Grant Award From the FDA: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Receives New Grant Award From the FDA


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it

Pfizer Declares Fourth-Quarter 2021 Dividendhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Declares Fourth-Quarter 2021 Dividend


Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent fourth-quarter 2021 dividend on the company’s common stock, payable December 6, 2021, to holders of the Common

Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Boosterhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the Pfizer-BioNTech

Agilent Announces Cash Dividend of 19.4 Cents per Share:
Agilent Announces Cash Dividend of 19.4 Cents per Share


Agilent Technologies, Inc. (NYSE: A) today announced that a quarterly dividend of 19.4 cents per share of common stock will be paid on Oct. 27, 2021, to all shareholders of record as of the close

Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countrieshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to expand their agreement with the U.S. government by providing an additional 500 million doses of the companies’

Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of

Premier Inc. to Participate in 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc. to Participate in 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021


Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that members of its management team are scheduled to participate in a fireside chat at the 2021 Cantor Virtual

Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and CEO, at the Cantor Global Healthcare Conference on Monday

Charles River Launches First Annual Healthcare Collaboration Report
Charles River Launches First Annual Healthcare Collaboration Report


Charles River Laboratories International, Inc. (NYSE: CRL) today released the results from its first annual Healthcare Collaboration Report, which identified Americans’ perceptions of healthcare’s

Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program : https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program


Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has paid off in full at maturity the remaining $64.4 million in principal amount outstanding of its 2.50% convertible senior notes due

Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Yearshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to

FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populationshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted

Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021
Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced four

Geisinger and Acadia Healthcare Hold Groundbreaking Ceremony for New Behavioral Health Center in Moosic
Geisinger and Acadia Healthcare Hold Groundbreaking Ceremony for New Behavioral Health Center in Moosic


Geisinger and Acadia Healthcare Company today held a groundbreaking ceremony for Geisinger Behavioral Health Center Northeast, a new 96-bed inpatient behavioral health facility. The event occurred